mercredi 18 septembre 2019

Onco Actu du 18 septembre 2019


1. BIOLOGIE



Enzyme active in cancer also protects normal cells [NIH]











3.1.1 PRÉVENTION - TABAC - E-CIGS



The vaping industry has close ties to Trump. His ban still caught them off guard. [Washington Post]











New York state ban on flavored e-cigarettes given final approval [Reuters]











4.12 BIOPSIES LIQUIDES



The Potential of ctDNA as a Prognostic Biomarker in Patients With Colorectal Cancer [AJMC]











4.9 DÉP., DIAG. & PRONO. - SEIN



Breast Cancer Screening Found Effective in Men at High Risk for the Disease [NYU Langone]











5. TRAITEMENTS



More Options, More Questions: Debating the Optimal Frontline Regimen for Multiple Myeloma [ASH]











5.10 TRAITEMENTS - ESSAIS



Pharma-Sponsored Oncology Trials Face Troubling Age Disparity Trend [TrialSite News]










5.12.13 IMMUNOTHÉRAPIES - BIOMARQUEURS



Scientists Identify A Subgroup Of Colorectal Cancer Patients Who Generally Do Poorly And Could Benefit From Immunotherapy [City of Hope]










Electronic nose can sniff out which lung cancer patients will respond to immunotherapy [EurekAlert!]











5.12.6 IMMUNOTHÉRAPIES - AMM



FDA Approves KEYTRUDA® (pembrolizumab) plus LENVIMA® (lenvatinib) Combination Treatment for Patients with Certain Types of Endometrial Carcinoma [Merck]











Simultaneous review decisions for pembrolizumab plus lenvatinib in Australia, Canada and US [FDA]










5.16 TRAITEMENTS - CHIRURGIE



Once-common hysterectomy technique linked to worse uterine cancer outcomes [Yale]











5.17 TRAITEMENTS - RADIOTHÉRAPIE



Targeted radiotherapy technique could cut treatment time from two months to two weeks [Institute of Cancer Research]











5.3 TRAITEMENTS - FDA, EMA, NICE...



Another day, another Gottlieb board seat: This time it's real-world evidence startup Aetion [Fierce Pharma]











Scott Gottlieb is once again joining a team that enjoyed good times at the FDA under his high-energy stint at the helm [EndPoints]











5.3.4 TRAITEMENTS - AMM (FDA, EMA,...)



FDA Approves Entrectinib Based on Tumor Genetics Rather Than Cancer Type [NCI]











5.6 ESMO



Janssen to Highlight Depth of Prostate Cancer and Solid Tumor Portfolios with Multiple Data Presentations at ESMO 2019 [ESMO]











5.9.1 ASTRO



Taking Baby Aspirin Improves Overall Survival for Patients With Head & Neck, Lung Cancer [Roswell Park]











Adding radiation after immunotherapy improves progression-free survival for some patients with metastatic lung cancer [ASTRO]











PACIFIC survival rates explained: Lung cancer spread reduced, new distant growth most often in the brain [ASTRO]











Artificial Intelligence accurately predicts radiation treatment side effects for patients with head and neck cancers [ASTRO]











Radiation May Lower Potential for Side Effects of CAR T Therapy in Non-Hodgkin’s Lymphoma [Penn Medicine]











6.1 OBSERVATION



UK still behind in cancer survival despite advances [NHS Choices]











6.7.1 IA/BIOINFORMATIQUE



Tech companies’ dangerous practice: using artificial intelligence to mine hidden health data [STAT]










6.8 COMMUNICATION



Fact-checking – by itself – is inherently flawed on health care topics [HealthNewsReview]